Pulmobiotics

pulmobio.com ↗ ·Barcelona ·Seed

Pulmobiotics is a Barcelona-based preclinical synthetic biology company developing engineered live biotherapeutic products (LBPs) for severe respiratory diseases, using a genetically attenuated Mycoplasma pneumoniae chassis that colonizes the lung and secretes therapeutic proteins locally. Spun out of the Centre for Genomic Regulation (CRG) in 2020, it has raised about €7M in equity and non-dilutive funding (a €2M seed from Invivo Ventures plus grants) and its lead program PB_LC is an inhaled therapy for non-small-cell lung cancer patients refractory to immunotherapy; the company has been reported to be raising a ~€12.5M Series A to reach first-in-human trials.

Founded

2020

Founders

Total funds raised

€2M

SectorsBiotech, Synthetic Biology, Live Biotherapeutics, Respiratory Disease, Oncology, Drug Discovery Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Luis Serrano

Co-founder & Chair of the Scientific Advisory Board

Maria Lluch-Senar

Co-founder & Chief Scientific Officer

Global models 4

Synlogic

United States · www.synlogictx.com ↗

Clinical-stage biotech whose engineered bacterial live biotherapeutics produce therapeutic effects in the body, with value built from drug pipeline milestones as at Pulmobiotics.

$300MComparable

Novome Biotechnologies

United States · www.novomebio.com ↗

Develops genetically engineered bacterial chassis that colonise the body and secrete therapeutic proteins locally, the same engineered live biotherapeutic approach.

$100MComparable

ActoGeniX

Belgium

Venture-backed developer of engineered bacteria that deliver therapeutic proteins at the site of disease; Intrexon acquired it in 2015.

$60MComparable